News & Blog

Abundance of KLRB1+ (CD161) T cells in anti-PD1 non responders coupled with enhanced tumor cytotoxicity of anti-CD161 (IMT-009) with anti-PD1 makes it a rational target for combination with anti-PD-(L)1 immunotherapy

ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA

Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

2023 – A Year in Retrospect

MEC in 4Q23: Pioneering the Future of Precision Medicine – More in 2024

Immunitas Therapeutics Appoints Annalisa D’Andrea, Ph.D., as Chief Scientific Officer

Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend

SonoThera’s CEO Ken Greenberg interviewed by Wilson Sonsini’s Dustin Luettgen in the latest edition of the Life Sciences Report